Aquaretic Effect of Lixivaptan, an Oral, Non-Peptide, Selective V2 Receptor Vasopressin Antagonist, in New York Heart Association Functional Class II and III Chronic Heart Failure Patients

Journal of the American College of Cardiology

Volumn 47, Issue 8, 2006, Pages 1615-1621

  Abraham, William T ^a   Shamshirsaz, Alireza A ^b   McFann, Kim ^b   Oren, Ron M ^c   Schrier, Robert W ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIXIVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

ADULT; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DIURESIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; FLATULENCE; HEADACHE; HEART FAILURE; HUMAN; HYPONATREMIA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TACHYCARDIA; URINE VOLUME; WATER RETENTION; XEROSTOMIA;

ADMINISTRATION, ORAL; CARDIAC OUTPUT, LOW; CHRONIC DISEASE; DIURESIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROLYTES; FEMALE; HORMONES; HUMANS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; RECEPTORS, VASOPRESSIN; SEVERITY OF ILLNESS INDEX; SODIUM; VASOPRESSINS;

EID: 33646054125     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.11.071     Document Type: Article

References (24)

1. Abraham W.T., and Schrier R.W. Renal salt and water handling in congestive heart failure. In: Hosenpud J.D., and Greenberg B.H. (Eds). Congestive Heart Failure. Pathophysiology, Diagnosis, and Comprehensive Approach to Management. 2nd edition (2000), Williams & Wilkins, Baltimore, MD 253-266
2. Lee W.H., and Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 73 (1986) 257-267
3. Lee D.S., Austivy P.C., Rouleau J.L., Liv P.P., Namimark D., and Tu J.V. Predicting mortality among patients hospitalized for heart failure. JAMA 290 (2003) 2581-2587
4. Anderson R.J., Cadnapaphornchai P., Harbottle J.A., Mcdonald K.M., and Schrier R.W. Mechanism of effect of thoracic inferior vena cava constriction on renal water excretion. J Clin Invest 54 (1974) 1473-1479
5. Kim J.K., Michel J.-B., Soubrier F., Durr J., Corvol P., and Schrier R.W. Arginine vasopressin gene expression in chronic cardiac failure in rats. Kidney Int 38 (1990) 818-822
6. Xu D.-L., Martine P.Y., Ohara M., et al. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest 99 (1997) 1500-1505
7. Szatalowicz V.L., Arnold P.E., Chaimovitz C., Bichet D., Berl T., and Schrier R.W. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 305 (1981) 263-266
8. Rigger G.A., Liebau G., and Kochsiek K. Antidiuretic hormone in congestive heart failure. Am J Med 72 (1982) 49-52
9. Rondeau E., de Lima J., Caillens H., Ardaillou R., Vahanian A., and Acar J. High plasma antiduretic hormone in patients with cardiac failure. influence of age. Miner Electrolyte Metab 8 (1982) 267-274
10. Goldsmith S.R., Francis G.S., and Cowley Jr. A.W. Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 58 (1986) 295-299
11. Yamamura Y., Ogawa H., Yamashita T., et al. Characterization of a novel aquaretic agent, OPC-31260, as an effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 105 (1992) 787-791
12. Serradeil-Le Gal C., Wagnon J., Valette G., et al. Nonpeptide vasopressin receptor antagonists. development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res 139 (2002) 197-210
13. Burrell L.M., Phillips P.A., Risvanis J., Chan R.K., Aldred K.L., and Johnston C.I. Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. Am J Physiol 275 (1998) H176-H182
14. Naitoh M., Suzuki H., Murakami M., et al. Effect of oral AVP antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 267 (1994) H2245-H2254
15. Chan P.S., Couplet J., Park H.C., et al. VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol 449 (1998) 439-443
16. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-35
17. Martin P.Y., Abraham W.T., Lieming X.U., et al. Selective V2-receptor vasopressin antagonist decreases urinary aquaporine-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 10 (1999) 2165-2170
18. Gerbes A.L., Gulberg V., Gines P., et al., VPA Study Group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist. a randomized double-blind multicenter trial. Gastroenterology 124 (2003) 933-939
19. Wong F., Blei A.T., Blendis L.M., and Thuluvath P.J. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia. a multicenter, randomized, placebo-controlled trial. Hepatology 37 (2003) 182-191
20. Gheorghiade M., Gattis W.A., O'Conner C.M., et al. Effect of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. a randomized controlled trial. JAMA 291 (2004) 1963-1971
21. Gheorghiade M., Niazi I., Ouyang J., et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure. Results from a double-blind, randomized trial. Circulation 107 (2003) 2690-2696
22. Palm C., and Gross P. V2-vasopressin receptor antagonist-mechanism of effect and clinical implication in hyponatremia. Nephrol Dial Transplant 14 (1999) 2559-2562
23. Tomaselli G.F., Beuckelmann D.J., Calkins H.C., et al. Sudden cardiac death in heart failure. The role of abnormal repolarization. Circulation 90 (1994) 2543-2549
24. Okada K., Ischikawa S., Caramelo C., Tsai P., and Schrier R.W. Enhancement of vascular action of argenine vasopressin by diminished extracellular sodium concentration. Kidney Int 44 (1993) 755-763